ClinicalTrials.gg

Program

SRC/YES1 Kinase Inhibitor NXP900

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Nuvectis Pharma.

Furthest: phase 1, since May 15, 20233 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nuvectis Pharma33 open or runningphase 1since May 15, 2023May 15, 2023Dec 2026phase 1 · NCT07315113

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05873686 · 140 enrolled · United States, United Kingdom
  2. Dec 18, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07315113 · 18 planned · United States
  3. Aug 20, 2026Phase 1 study in ALK PositiveNCT07784959 · 54 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07315113
  2. Mar 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05873686
  3. Aug 2027Primary completion: phase 1 study in ALK PositiveNCT07784959

TargetBeta

SRC →YES1 →read by rule
“An orally bioavailable inhibitor of SRC family of kinases (SFK), including SRC and YES1, ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07784959ALK Positive · United States1RecruitingAug 202754
NCT07315113Carcinoma, Non-Small-Cell Lung · United States1RecruitingDec 202618
NCT05873686Carcinoma, Non-Small-Cell Lung · United States, United Kingdom1Active, not recruitingMar 2027140

How it is read

Names in the registry

  • “NXP900”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.